An investigation for investors in NASDAQ:RGLS shares was announced over potential securities laws violations by Regulus Therapeutics and certain of its directors and officers.
Investors who purchased shares of Regulus Therapeutics Inc (NASDAQ:RGLS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Regulus Therapeutics Inc (NASDAQ:RGLS) concerning whether a series of statements by Regulus Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On June 27, 2016, Regulus Therapeutics Inc announced during aftermarket hours that it received verbal notice from the U.S. Food and Drug Administration (“FDA”) that the FDA had placed the Regulus Therapeutics’ investigational new drug for the treatment of chronic hepatitis C virus infection on clinical hold after a second serious adverse event of jaundice was reported. Shares of Regulus Therapeutics Inc declined on June 28, 2016 to as low as $2.44 per share.
On July 13, 2016, NASDAQ:RGLS shares closed at $3.37 per share.
Those who purchased NASDAQ:RGLS shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com